TNFβ was most variable (cv = 176%), driven by high levels in esophageal cancer, followed by IL-1RA (high in ovarian cancer, low in melanoma and renal cancer, cv = 110%) and FLT3L (high in breast cancer, cv = 106%). This evidence concerns the gene IL6R and breast cancer.